GleamWall
中文EN

BHVN Biohaven Ltd.

Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$101.85M$100.81M$103.83M$121.94M$141.17M$184.37M$187.58M$167.47M
SG&A expense$24.57M$24.09M$26.60M$20.79M$28.21M$27.33M$33.98M$22.46M
Operating income-$126.42M-$124.90M-$130.43M-$142.73M-$169.38M-$211.70M-$221.56M-$189.93M
Pretax income-$129.34M-$136.92M-$130.26M-$145.20M-$173.22M-$197.89M-$221.07M-$186.79M
Income tax-$64,000$391,000$272,000$351,000$221,000$261,000$609,000$48,000
Net income-$129.28M-$137.31M-$130.53M-$145.56M-$173.44M-$198.15M-$221.68M-$186.84M
EBITDA-$125.85M-$124.28M-$128.06M-$140.16M-$168.28M-$210.64M-$219.31M-$187.47M
EPS (basic)-0.86-0.91-0.88—-1.64-1.94-2.17—
EPS (diluted)-0.86-0.91-0.88—-1.64-1.94-2.17—
Weighted avg. shares (diluted)151.04M150.64M147.62M—105.82M102.37M101.94M—
Balance sheet
Cash & equivalents$95.75M$238.03M$273.07M$229.96M$184.85M$165.80M$98.42M$102.54M
Short-term investments$65.37M$29.83M$74.74M$89.18M$75.37M$239.18M$224.33M$386.86M
Current assets$191.51M$296.56M$385.65M$368.33M$323.62M$474.83M$382.76M$538.47M
PP&E, net$14.70M$15.09M$15.26M$15.96M$17.52M$18.59M$17.79M$17.32M
Goodwill$1.39M$1.39M$1.39M$1.39M$1.39M$1.39M$1.39M$1.39M
Intangibles$18.40M$18.40M$18.40M$18.40M$18.40M$18.40M$18.40M$18.40M
Total assets$263.68M$370.74M$466.41M$451.45M$409.12M$550.41M$458.95M$615.11M
Current liabilities$62.77M$62.66M$52.08M$115.93M$113.02M$124.32M$164.03M$154.23M
Total liabilities$361.92M$358.52M$336.91M$399.38M$426.28M$415.83M$199.45M$191.67M
Shareholders' equity-$98.25M$12.22M$129.50M$52.07M-$17.16M$134.59M$259.50M$423.44M
Shares outstanding151.06M151.02M150.51M132.78M105.80M105.78M102.10M101.22M
Cash flow statement
Operating cash flow-$106.85M-$85.10M-$149.92M-$130.66M-$145.72M-$167.94M-$165.12M-$170.74M
Capital expenditure$180,000$454,000$0$8,000$13,000$233,000$461,000$49,000
Free cash flow-$107.03M-$85.55M-$149.92M-$130.67M-$145.73M-$168.17M-$165.59M-$170.79M
Investing cash flow-$35.33M$44.82M$15.21M-$13.74M$164.97M-$15.55M$164.88M-$87.68M
Financing cash flow$211,000$3.80M$179.02M$188.80M$122,000$249.83M$369,000$272.85M
Depreciation & amortization$569,000$621,000$2.37M$2.57M$1.10M$1.06M$2.25M$2.46M
Stock-based compensation$18.62M$19.16M$28.29M$16.95M$21.54M$20.81M$53.06M$12.69M

Free plan shows the latest 8 periods; Pro shows all 23 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.